- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
20/20 Biolabs and Applied DNA Sciences Compared in Financial Survey
Analysts weigh the strengths of the two small-cap biotech services companies
Mar. 18, 2026 at 9:18am
Got story updates? Submit your updates here. ›
A financial analysis compares the performance and prospects of 20/20 Biolabs (NASDAQ:AIDX) and Applied DNA Sciences (NASDAQ:BNBX), two small-cap biotech services companies. The report examines factors like dividends, analyst recommendations, profitability, and institutional ownership to determine which stock is the superior investment.
Why it matters
The comparison of these two small-cap biotech firms provides insight into the competitive landscape and growth potential of the sector. As investors seek opportunities in the dynamic life sciences industry, understanding the relative strengths of similar companies can inform investment decisions.
The details
The analysis finds that 20/20 Biolabs has higher revenue and earnings than Applied DNA Sciences. 20/20 Biolabs also outperforms Applied DNA Sciences on 5 out of 8 key metrics, including net margins, return on equity, and return on assets. However, Applied DNA Sciences has stronger institutional ownership at 22.2% compared to 0% for 20/20 Biolabs.
- The report was published on March 18, 2026.
The players
20/20 Biolabs
A small-cap biotech services company focused on developing and commercializing AI-powered blood tests for early cancer and disease detection.
Applied DNA Sciences
A small-cap biotech services company that develops and markets DNA-based technology solutions for diagnostics, drug development, and supply chain security.
The takeaway
The financial analysis highlights the competitive strengths of 20/20 Biolabs, which has outperformed Applied DNA Sciences on key metrics like revenue, earnings, and profitability. However, Applied DNA Sciences' stronger institutional backing suggests it may also warrant consideration by investors seeking exposure to innovative biotech services companies.
